Kaken Pharmaceutical Co., Ltd.

4521

JP3207000005

Pharmaceuticals

Delayed Japan Exchange Other stock markets 01:22:16 2024-05-10 am EDT			5-day change	1st Jan Change
3,506 ^JPY	+0.66%		+1.12%	+4.53%

2023	Kaken Pharmaceutical Co., Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Full Year Ending March 31, 2024	CI
2023	Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024	CI

Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

February 15, 2022 at 03:00 am EST

Kaken Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2022. For the period, the company expected net sales of JPY 79,200 million, operating profit of JPY 18,800 million, profit attributable to owners of parent of JPY 14,000 million and basic earnings per share of JPY 370.19.

Latest news about Kaken Pharmaceutical Co., Ltd.

Kaken Pharmaceutical Co., Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Full Year Ending March 31, 2024	Nov. 14	CI
Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024	Nov. 14	CI
Kaken Pharmaceutical Co., Ltd.(TSE:4521) dropped from FTSE All-World Index	23-09-18	CI
Kaken Pharmaceutical’s Attributable Profit Drops 13.7% in Fiscal Q1 due to Higher Expenses	23-08-17	MT
Kaken Pharmaceutical Co., Ltd. Provides Dividend Forecast for Second Quarter of 2024 and Fiscal Year Ending March 31, 2024	23-08-17	CI
Kaken Pharmaceutical Co., Ltd. Provides Consolidated Financial Forecast for Fiscal Year Ending March 31, 2024	23-08-17	CI
MediWound Partner Launches NexoBrid in Japan	23-08-01	MT
Botanix Pharmaceuticals Partner Secures Sublicense, Distribution Deal in Korea	23-06-05	MT
Kaken Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-10	CI
Cymabay Taps Kaken Pharmaceutical to Develop, Commercialize Liver Disease Drug Candidate in Japan	23-01-09	MT
Sector Update: Healthcare Stocks Rise Friday, Mostly Trail Other Sectors	23-01-06	MT
Top Midday Gainers	23-01-06	MT
Sector Update: Health Care Stocks Gain Premarket Friday	23-01-06	MT
Sector Update: Health Care	23-01-06	MT
Top Premarket Gainers	23-01-06	MT
North American Morning Briefing : Stock Futures Soft as Investors Eye Jobs Report	23-01-06	DJ
Spruce Biosciences, Kaken Sign Licensing Deal for Tildacerfont in Japan; Spruce Shares Surge After Hours	23-01-05	MT
Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan	23-01-05	CI
MediWound's Partner Kaken Pharmaceutical Receives Marketing Approval of NexoBrid in Japan, Shares Rise Pre-Bell	22-12-23	MT
MediWound Ltd. Expands NexoBrid’s Global Presence with Marketing Approval in Japan with Kaken Pharmaceutical	22-12-23	CI
Kaken Pharmaceutical to Invest $7 Million in Venture Capital Fund	22-11-09	MT
Tranche Update on Kaken Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.	22-07-28	CI
Kaken Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2022, has closed with 350,000 shares, representing 0.93% for ¥692.31 million.	22-07-26	CI
Tranche Update on Kaken Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2022.	22-06-30	CI
Kaken Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023	22-05-25	CI

Chart Kaken Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Kaken Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3,483 JPY

Average target price

3,500 JPY

Spread / Average Target

+0.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KAKEN PHARMACEUTICAL CO., LTD.	+4.53%	848M
ELI LILLY AND COMPANY	+32.36%	695B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	361B
MERCK & CO., INC.	+19.46%	330B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	239B
NOVARTIS AG	+6.68%	204B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	168B

Other Pharmaceuticals